

## Launch of Ipsos PersonaBot, a groundbreaking Alpowered solution to enhance segmentation research

Paris, July 02, 2024 - Ipsos, one of the world's leading market research companies, announces the launch of Ipsos PersonaBot, an Al-powered tool that allows organisations to 'converse' with personas representing their target segments. Developed as both a consumer solution and a solution for the healthcare sector, Ipsos PersonaBot is powered by Ipsos Facto, the Group's generative Al platform.

Designed to augment the utility and value of segmentation studies, Ipsos PersonaBot uses AI to enable stakeholders across the organisation to interact with the personas identified in their segmentation study as if they were real people. Via a secure portal, they can ask questions about everything from attitudes and behaviours to communication needs to preferences regarding messages and channels – and probe further for deeper insights. Personas can be questioned individually or together, in the style of a focus group.

Christophe Cambournac, Global Head of Service Lines at Ipsos, commented: "The launch of Ipsos PersonaBot is a further step in leveraging the power of AI to help our clients make faster and smarter marketing decisions. We are proud to be ahead of the game in terms of AI in the market research industry, and to be able to provide a new dimension of insights and increased ROI for our clients."

While segmentation studies have the potential to support an array of marketing activities, often comprising a significant chunk of market research spend, many companies find it challenging to realise their full potential and hence, maximize the return on investment. Ipsos PersonaBot addresses this challenge by widening internal access to the segmentation, expanding its uses and applications, increasing stakeholders' engagement levels and, ultimately, augmenting the depth of insight delivered.

The consumer version of PersonaBot can be leveraged by virtually any manufacturer or service provider. Healthcare PersonaBot has been developed specifically to support the

+ 33 1 41 98 90 34





activation of healthcare segmentations and was developed in accordance with healthcare regulatory requirements.

## **ABOUT IPSOS**

Ipsos is one of the largest market research and polling companies globally, operating in 90 markets and employing nearly 20,000 people.

Our passionately curious research professionals, analysts and scientists have built unique multi-specialist capabilities that provide true understanding and powerful insights into the actions, opinions and motivations of citizens, consumers, patients, customers, or employees. Our 75 business solutions are based on primary data from our surveys, social media monitoring, and qualitative or observational techniques.

"Game Changers" – our tagline – summarizes our ambition to help our 5,000 clients navigate with confidence our rapidly changing world.

Founded in France in 1975, Ipsos has been listed on the Euronext Paris since July 1, 1999. The company is part of the SBF 120, Mid-60 indices, STOXX Europe 600 and is eligible for the Deferred Settlement Service (SRD). ISIN code FR0000073298, Reuters ISOS.PA, Bloomberg IPS: FP www.ipsos.com

35 rue du Val de Marne 75 628 Paris, Cedex 13 France Tél. + 33 1 41 98 90 00



+ 33 1 41 98 97 65

